Welcome to our dedicated page for Nutra Pharma SEC filings (Ticker: NPHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
nutra pharma corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. the company carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. currently, nutra pharma offers several drug products for sale for the treatment of pain: nyloxin, the first over-the-counter (otc) pain reliever clinically proven to treat moderate to severe (stage 2) chronic pain, and nyloxin extra strength, the only non-narcotic and non-addictive treatment for severe (stage 3) pain. see: www.nyloxin.com nutra pharma also offers pet pain-away: a product aimed at treating moderate to severe chronic pain in companion animals. pet pain-away is specifically indicated to treat pain from hip dysplasia, arthritNutra Pharma Corp reports Q2 2025 results showing net income of $369,577, reversing a prior-year quarterly loss, largely due to a $704,622 gain from changes in the fair value of convertible notes and derivatives and a $53,526 gain on debt settlements.
Core operations remain weak. For the three months ended June 30, 2025, net sales were $84,532 plus $37,611 to a related party, generating gross profit of only $75,628 against selling, general and administrative expenses of $366,157, resulting in a loss from operations of $290,529. For the six-month period, the company recorded a net loss of $1,035,346.
The balance sheet is highly leveraged, with total assets of $859,068 versus total liabilities of $16,692,328, including $9,345,780 of current debt and $924,516 of derivative liabilities. Stockholders’ deficit was $15,833,260, and the accumulated deficit reached $77,266,483.
Liquidity is strained: cash was only $79,069 at June 30, 2025, after using $693,376 in operating cash during the first half, funded mainly by $810,056 of new convertible notes and officer loans. Management discloses a working capital deficit of $15,888,753, numerous defaulted debts, dependence on external financing, and explicitly states there is substantial doubt about the company’s ability to continue as a going concern, exacerbated by its common stock trading on the OTC Market Group’s Expert Market, which restricts capital-raising options.
Nutra Pharma Corp. reported higher net sales but a much larger loss for the quarter ended March 31, 2025. Net sales rose to $73,974 from $37,732, plus $36,420 of related-party sales, yet the company posted a net loss of $1,404,923 versus $426,934 a year earlier. The deeper loss was driven by operating expenses of $418,150, interest costs, and a $1,007,309 loss from changes in the fair value of convertible notes and derivatives.
Nutra Pharma ended the quarter with only $13,843 of cash, total assets of $775,179, and total liabilities of $16,988,016, resulting in a stockholders’ deficit of $16,212,837. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing an accumulated deficit of $77,636,060, a working capital deficit of $16,296,563, heavy debt—much of it in default, including $9,057,034 of notes—and tight access to capital with its stock on the OTC Expert Market. The company has also accrued $680,235 for an SEC legal judgment and relies on new convertible debt financings to fund operations while it seeks to grow sales of its pain relief products.
Nutra Pharma Corp. filed its annual report detailing 2024 results and continued financial strain. The biopharmaceutical company markets homeopathic pain products like Nyloxin, Pet Pain-Away, Equine Pain-Away and Luxury Feet, and is developing drug candidates RPI-78M and RPI-MN for autoimmune, neurological and viral diseases.
Nutra Pharma reported a 2024 net loss of $1,285,663, following a 2023 net loss of $1,393,356, and disclosed material weaknesses in internal control over financial reporting. Management warns there is substantial doubt about its ability to continue as a going concern without new financing and higher product sales.
The company holds an FDA Orphan Drug Designation for RPI-78M in pediatric multiple sclerosis and aims to start Phase I/II trials in 2026, subject to funding. As of February 17, 2026, Nutra Pharma had 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding, and reported non‑affiliate equity market value of $6,762,239 as of its most recent second quarter.
Nutra Pharma Corp. reports another quarterly loss and highlights serious financial strain in its Q3 2024 report. For the nine months ended September 30, 2024, net sales were $164,436 with additional related-party sales of $106,184, while the company recorded a net loss of $1,054,756, similar to the prior year’s loss. Gross profit fell compared with 2023 as operating expenses continued to exceed revenue.
The balance sheet shows total assets of $558,838 against total liabilities of $15,378,402, resulting in a stockholders’ deficit of $14,819,564. The company discloses that it had no cash at period-end, a working capital deficit of $14,902,502, and significant debt, much of it in default or convertible. Management states there is substantial doubt about its ability to continue as a going concern and notes that common stock trades on the OTC Expert Market, which limits capital-raising options.